| Style | Citing Format |
|---|---|
| MLA | Davoudimonfared E, Khalili H. "Reply to Dorgham Et Al., “Considering Personalized Interferon Beta Therapy for Covid-19”." Antimicrobial Agents and Chemotherapy, vol. 65, no. 4, 2021, pp. -. |
| APA | Davoudimonfared E, Khalili H (2021). Reply to Dorgham Et Al., “Considering Personalized Interferon Beta Therapy for Covid-19”. Antimicrobial Agents and Chemotherapy, 65(4), -. |
| Chicago | Davoudimonfared E, Khalili H. "Reply to Dorgham Et Al., “Considering Personalized Interferon Beta Therapy for Covid-19”." Antimicrobial Agents and Chemotherapy 65, no. 4 (2021): -. |
| Harvard | Davoudimonfared E, Khalili H (2021) 'Reply to Dorgham Et Al., “Considering Personalized Interferon Beta Therapy for Covid-19”', Antimicrobial Agents and Chemotherapy, 65(4), pp. -. |
| Vancouver | Davoudimonfared E, Khalili H. Reply to Dorgham Et Al., “Considering Personalized Interferon Beta Therapy for Covid-19”. Antimicrobial Agents and Chemotherapy. 2021;65(4):-. |
| BibTex | @article{ author = {Davoudimonfared E and Khalili H}, title = {Reply to Dorgham Et Al., “Considering Personalized Interferon Beta Therapy for Covid-19”}, journal = {Antimicrobial Agents and Chemotherapy}, volume = {65}, number = {4}, pages = {-}, year = {2021} } |
| RIS | TY - JOUR AU - Davoudimonfared E AU - Khalili H TI - Reply to Dorgham Et Al., “Considering Personalized Interferon Beta Therapy for Covid-19” JO - Antimicrobial Agents and Chemotherapy VL - 65 IS - 4 SP - EP - PY - 2021 ER - |